The Rise and Fall of BioNTech: Navigating the Shift from Pandemic Hero to Oncology Pioneer
BioNTech faces financial challenges as vaccine demand declines; fourth-quarter 2024 earnings fell to €1.08 per share, from €1.90 the previous year. Revenues decreased to €1.19 billion, with a reported net…